<DOC>
	<DOCNO>NCT00938899</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability pharmacokinetics increase oral dos TMC435350 single repeat dosing , follow open label repeat dose session 6 HCV genotype1 infect patient .</brief_summary>
	<brief_title>TMC435350-TiDP16-C101 - A Study Examine Safety , Tolerability Pharmacokinetics Increasing Oral Doses TMC435350 After Single Repeated Dosing</brief_title>
	<detailed_description>This trial randomize , double blind , placebo-controlled trial determine safety , tolerability pharmacokinetics TMC435350 single multiple oral dos take healthy non-Hepatitis C Virus infect ( non-HCV ) participant , follow open label repeat dos take 6 HCV-genotype 1 infected participant ( non-placebo control ) . The single dose escalation part trial consist 6 session ( Sessions Ia VIa ) include 2 panel 9 healthy non-HCV infected participant ( Panels 1 2 ) . The dose test drug consecutively escalate . Doses 50 mg , 100 mg , 200 mg , 400 mg , 800 mg 1200 mg TMC435350 placebo administer single oral administration alternate 2 panel . In session , 6 participant receive active treatment 3 participant receive placebo breakfast . The treatment schedule ensure 3 session particpant receive active treatment twice placebo . There washout period least 10 day consecutive TMC435350 placebo dosings within panel . Participants Panel 1 additional session investigate food effect : single dose TMC435350 test fasted condition ( Session VIIa ) . Food effect investigate 200 mg dose Panel 1 , unless available concentration drug blood safety data previous session prove unnecessary . Multiple dosing start Sessions Ia ( single dose 50 mg ) , IIa ( single dose 100 mg ) IIIa ( single dose 200 mg ) find safe tolerable . The multiple dose escalation part trial consist 4 consecutive session ( Sessions Ib IVb ) 4 panel 9 healthy non-HCV infected participant ( Panels 3 , 4 , 5 6 ) . In session , 6 participant receive active treatment 3 participant receive placebo . TMC435350 placebo administer 5 consecutive day . As potential food effect yet know , administration meal . Treatment anticipated twice daily dos 50 mg , 100 mg , 200 mg 400 mg . The available concentration drug blood determine 72 hour first dose , case single dose TMC435350 give ( Sessions Ia VIIa , perform , Session VIIIa ) . In case multiple dosing ( Sessions Ib IVb ) , full pharmacokinetic profile TMC435350 determine first dosage interval ( e.g . 24 hour first dose b.i.d . regimen ) 72 hour last dose . Safety tolerability evaluate continuously document ( safety report ) , 24-hours interim PK data last dose , step next dose session . After completion healthy participant session , open label session ( Ic ) HCV genotype 1 infect participant add . The trial population ( Panel 7 ) include 6 male female , non-responder HCV-genotype 1 infected participant HCV viral load least 50000 IU/mL . These participant treat Panel 7 follow-up visit , 5 day dose period . One dose regimen select show safe healthy participant close possible maximum tolerate dose , administer 5 day . In addition drug safety PK parameter , viral load determine plasma .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Healthy participant must nonsmoker , normal weight , normal ECG , healthy basis medical evaluation , physical examination , medical history , ECG , vital sign , laboratory result HCV patient must normal weight , normal ECG , chronic genotype 1 HCV infection , nonresponders relapsers previous treatment regimen HCV viral load least 50000 IU/mL plasma screening . Patients history cardiac disease , HIV1 HIV2 test Women childbearing potential History evidence abuse alcohol , barbiturate , amphetamine , recreational narcotic drug use , hepatitis A , B C infection Positive urine drug test Any active underlying disease History drug allergy hypersensitivity Participation investigational trial within 30 day prior first intake study medication Recent donation blood Abnormal laboratory value HCV patient cardiac disease , coinfections HIV1 , HIV2 liver infection HCV Women childbearing potential Participants agree use reliable birth control method last trial visit Drug abuse Cardiovascular , hepatic renal disease , diabetes , epilepsy , skin psychiatric disease Enrolled another clinical trial 90 day prior screen Evidence Child Pugh B C liver disease Having receive polymerase protease inhibitor treatment last 6 month Abnormal laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC435350-TiDP16-C101</keyword>
	<keyword>TMC435350-C101</keyword>
	<keyword>TMC435350</keyword>
	<keyword>HCV</keyword>
</DOC>